Melin­ta Ther­a­peu­tics nabs FDA nod for more con­ve­nient re­work of an­tibi­ot­ic Or­bac­tiv, a for­mer Eli Lil­ly can­di­date

As pres­sure ris­es to ad­dress the su­per­bug cri­sis, Melin­ta Ther­a­peu­tics says it now has a more con­ve­nient op­tion to treat those with an­tibi­ot­ic-re­sis­tant skin in­fec­tions.

Melin­ta got the OK for a new-and-im­proved for­mu­la­tion of its an­tibi­ot­ic ori­ta­vancin in acute bac­te­r­i­al skin and skin struc­ture in­fec­tions (AB­SS­SI) caused by sus­cep­ti­ble iso­lates of Gram-pos­i­tive mi­croor­gan­isms, in­clud­ing MR­SA, the com­pa­ny an­nounced on Mon­day. The drug, mar­ket­ed as Kimyr­sa, can be ad­min­is­tered over one hour as op­posed to Melin­ta’s ear­li­er Or­bac­tiv, which takes three.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.